Orexo AB (publ) (ORX.ST)
SEK 14.36
(2.57%)
SEK 14.36
(2.57%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 448.4 Million SEK | -13.6% |
| 2022 | 519 Million SEK | -2.13% |
| 2021 | 530.3 Million SEK | 1018.78% |
| 2020 | 47.4 Million SEK | -85.32% |
| 2019 | 322.9 Million SEK | 0.72% |
| 2018 | 320.6 Million SEK | 0.44% |
| 2017 | 319.2 Million SEK | -19.76% |
| 2016 | 397.8 Million SEK | -19.53% |
| 2015 | 494.33 Million SEK | 0.12% |
| 2014 | 493.76 Million SEK | 374.4% |
| 2013 | 104.08 Million SEK | -8.36% |
| 2012 | 113.57 Million SEK | -0.82% |
| 2011 | 114.51 Million SEK | 21.28% |
| 2010 | 94.42 Million SEK | 637.66% |
| 2009 | 12.8 Million SEK | 34.6% |
| 2008 | 9.51 Million SEK | 0.0% |
| 2007 | - SEK | 0.0% |
| 2006 | - SEK | 0.0% |
| 2005 | - SEK | 0.0% |
| 2004 | - SEK | 0.0% |
| 2003 | - SEK | 0.0% |
| 2002 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 5.9 Million SEK | -100.0% |
| 2024 Q2 | 458.5 Million SEK | 0.0% |
| 2024 Q3 | 459.3 Million SEK | 0.17% |
| 2023 FY | 448.4 Million SEK | -13.6% |
| 2023 Q1 | 508.2 Million SEK | -2.08% |
| 2023 Q3 | 457.4 Million SEK | -7.65% |
| 2023 Q4 | 448.4 Million SEK | -1.97% |
| 2023 Q2 | 495.3 Million SEK | -2.54% |
| 2022 Q1 | 526.7 Million SEK | -0.68% |
| 2022 FY | 519 Million SEK | -2.13% |
| 2022 Q4 | 519 Million SEK | -0.35% |
| 2022 Q2 | 523.7 Million SEK | -0.57% |
| 2022 Q3 | 520.8 Million SEK | -0.55% |
| 2021 Q2 | 534.7 Million SEK | -0.06% |
| 2021 Q1 | 535 Million SEK | 1028.69% |
| 2021 FY | 530.3 Million SEK | 1018.78% |
| 2021 Q4 | 530.3 Million SEK | -0.51% |
| 2021 Q3 | 533 Million SEK | -0.32% |
| 2020 Q3 | 268.2 Million SEK | -1.61% |
| 2020 Q4 | 47.4 Million SEK | -82.33% |
| 2020 Q1 | 303.3 Million SEK | -6.07% |
| 2020 Q2 | 272.6 Million SEK | -10.12% |
| 2020 FY | 47.4 Million SEK | -85.32% |
| 2019 Q1 | 366.3 Million SEK | 14.25% |
| 2019 FY | 322.9 Million SEK | 0.72% |
| 2019 Q4 | 322.9 Million SEK | -1.37% |
| 2019 Q3 | 327.4 Million SEK | -9.88% |
| 2019 Q2 | 363.3 Million SEK | -0.82% |
| 2018 Q3 | 320.2 Million SEK | 0.13% |
| 2018 Q1 | 319.5 Million SEK | 0.09% |
| 2018 Q2 | 319.8 Million SEK | 0.09% |
| 2018 FY | 320.6 Million SEK | 0.44% |
| 2018 Q4 | 320.6 Million SEK | 0.12% |
| 2017 Q4 | 319.2 Million SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q2 | - SEK | -100.0% |
| 2017 FY | 319.2 Million SEK | -19.76% |
| 2017 Q1 | 339.4 Million SEK | -14.68% |
| 2016 FY | 397.8 Million SEK | -19.53% |
| 2016 Q4 | 397.8 Million SEK | -19.81% |
| 2016 Q3 | 496.1 Million SEK | 0.12% |
| 2016 Q2 | 495.5 Million SEK | 0.12% |
| 2016 Q1 | 494.9 Million SEK | 0.11% |
| 2015 Q4 | 494.33 Million SEK | 0.13% |
| 2015 Q2 | 493.1 Million SEK | -0.12% |
| 2015 Q1 | 493.7 Million SEK | -0.01% |
| 2015 FY | 494.33 Million SEK | 0.12% |
| 2015 Q3 | 493.7 Million SEK | 0.12% |
| 2014 Q2 | 493.6 Million SEK | 376.91% |
| 2014 Q1 | 103.5 Million SEK | -0.56% |
| 2014 Q3 | 493.7 Million SEK | 0.02% |
| 2014 Q4 | 493.76 Million SEK | 0.01% |
| 2014 FY | 493.76 Million SEK | 374.4% |
| 2013 Q2 | 109.9 Million SEK | 2.9% |
| 2013 FY | 104.08 Million SEK | -8.36% |
| 2013 Q4 | 104.08 Million SEK | 1110.24% |
| 2013 Q3 | 8.6 Million SEK | -92.17% |
| 2013 Q1 | 106.8 Million SEK | -5.96% |
| 2012 Q4 | 113.57 Million SEK | 2.41% |
| 2012 Q3 | 110.9 Million SEK | 1.74% |
| 2012 FY | 113.57 Million SEK | -0.82% |
| 2012 Q1 | 107.7 Million SEK | -5.95% |
| 2012 Q2 | 109 Million SEK | 1.21% |
| 2011 FY | 114.51 Million SEK | 21.28% |
| 2011 Q4 | 114.51 Million SEK | 6.51% |
| 2011 Q3 | 107.51 Million SEK | 14.46% |
| 2011 Q2 | 93.93 Million SEK | 3.25% |
| 2011 Q1 | 90.97 Million SEK | -3.65% |
| 2010 Q3 | 91.51 Million SEK | 3.29% |
| 2010 Q4 | 94.42 Million SEK | 3.18% |
| 2010 FY | 94.42 Million SEK | 637.66% |
| 2010 Q1 | - SEK | -100.0% |
| 2010 Q2 | 88.59 Million SEK | 0.0% |
| 2009 FY | 12.8 Million SEK | 34.6% |
| 2009 Q3 | 25.8 Million SEK | 0.0% |
| 2009 Q4 | 12.8 Million SEK | -50.4% |
| 2008 Q4 | 9.51 Million SEK | 0.0% |
| 2008 FY | 9.51 Million SEK | 0.0% |
| 2007 FY | - SEK | 0.0% |
| 2006 FY | - SEK | 0.0% |
| 2005 FY | - SEK | 0.0% |
| 2004 FY | - SEK | 0.0% |
| 2003 FY | - SEK | 0.0% |
| 2002 FY | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 26.35 Million SEK | -1601.32% |
| Enzymatica AB (publ) | 24.88 Million SEK | -1701.961% |
| Enorama Pharma AB (publ) | 303 Thousand SEK | -147886.799% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
| Moberg Pharma AB (publ) | 3.46 Million SEK | -12833.372% |
| Nanexa AB (publ) | 2.08 Million SEK | -21385.386% |
| Newbury Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| ODI Pharma AB | - SEK | -Infinity% |
| Probi AB (publ) | 38.21 Million SEK | -1073.453% |
| Swedencare AB (publ) | 1.44 Billion SEK | 68.887% |
| Swedish Orphan Biovitrum AB (publ) | 11.35 Billion SEK | 96.051% |
| Toleranzia AB | 850 Thousand SEK | -52652.941% |
| Vivesto AB | 5.18 Million SEK | -8554.7% |